Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NovoTTF-200M device, Best Standard of Care · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| NovoTTF-200M device | EXPERIMENTAL | NovoTTF-200M device Patients undergo SRS followed by continuous TTFields treatment using the NovoTTF-200M device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine. |
| Best Standard of Care | ACTIVE_COMPARATOR | Patients will undergo SRS alone and be treated with the best known standard of care for Non-Small Cell Lung Cancer metastatic to the brain. |
| Name | Type | Description |
|---|---|---|
| NovoTTF-200M device | DEVICE | - |
| Best Standard of Care | OTHER | - |
Inclusion Criteria: 1. 18 years of age and older 2. Life expectancy of ≥ 3 months 3. New diagnosis of brain metastases from a histologically or cytologically confirmed primary or metastatic NSCLC tumor within 5 years of registration on the study. If the original histological proof of malignancy is ...
The NovoTTF-200M device is used for the treatment of brain metastases from non-small cell lung cancer (NSCLC). It is being studied as an addition to radiosurgery for patients with 1 to 10 brain metastases. The device delivers tumor treating fields, a form of electric field therapy, to the brain.
The NovoTTF-200M device targets tumor cells by delivering tumor treating fields (TTFields), which are low-intensity, alternating electric fields that disrupt cancer cell division. This mechanism is being evaluated in brain metastases from non-small cell lung cancer, where the device is used in combination with radiosurgery.
The NovoTTF-200M device is developed by NovoCure Limited, a company traded under the ticker NVCR. NovoCure is an oncology company focused on developing tumor treating fields therapy for various solid tumors, including brain metastases from non-small cell lung cancer.
The NovoTTF-200M device is in Phase 3 clinical development. It is an investigational device, not yet approved, and is being evaluated in a completed Phase 3 study for brain metastases from non-small cell lung cancer. The study was a pivotal, open-label, randomized trial.
The NovoTTF-200M device was studied in a single Phase 3 clinical trial with the identifier NCT02831959. This completed trial enrolled 298 participants and evaluated radiosurgery with or without tumor treating fields for 1 to 10 brain metastases from non-small cell lung cancer. The trial was conducted across multiple countries.
The NovoTTF-200M device is a specific device that delivers tumor treating fields (TTFields) therapy. It is designed to apply alternating electric fields to the brain to treat metastases from non-small cell lung cancer. The device is being tested in combination with radiosurgery in a Phase 3 trial.